Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Acute Ischemic Stroke

Recruiting Phase 1 Phase 2 Interventional Study
Acute Ischemic Stroke
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 80
Sex
Any
Trial phase
Phase 1/2
Study type
Interventional
Purpose
Treatment
Participants needed
72 (estimated)
Sponsor
Dongzhimen Hospital, Beijing · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of this study is to assess the effectiveness and safety of Qingre Huatan formula versus placebo on preventing early neurological deterioration in patients with acute ischemic stroke within 48 hours after onset.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Inpatients diagnosed with acute ischemic stroke. Inpatients diagnosed of acute ischemic stroke. 2. Meet the criteria of TCM phlegm-heat syndrome 3. Patients at high-risk of END : Magnetic resonance imaging (MRI) reveals new ischemic lesions, with DWI-ASPECTS score ≤ 7, or pre…
Contacts

No contact information available.